Merck opens new S$20m lab offering biosafety testing services

Singapore

PHARMACEUTICAL firms in Asia can get quicker, more accessible testing services for their biological drug products from Merck's first BioReliance laboratory in the region, part of the pharmaceutical giant's new S$20 million, 3,800-square-metre facility in Singapore which was officially opened on Tuesday.

Designed based on feedback from customers in Asia, the BioReliance biosafety testing lab offers services such as lot release testing, which ensures clients' products are safe for release, and viral clearance, which validates the ability of clients' manufacturing processes to remove viral contamination. It also provides biorepository cell banking: helping clients store copies of the cell lines used in their production, to mitigate risks and provide greater convenience.